Magee-Womens Hospital of UPMC and CMU Develop App for High-Risk Pregnant Women | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Magee-Womens Hospital of UPMC and CMU Develop App for High-Risk Pregnant Women

May 1, 2017
by Heather Landi
| Reprints

Maternal-fetal medicine specialists at Magee-Womens Hospital of UPMC collaborated with decision scientists at Carnegie Mellon University (CMU), also based in Pittsburgh, to develop and test a personalized smartphone application designed to combat preterm birth by engaging a typically hard-to-reach population of pregnant women.

The findings of a pilot study, reported in the Journal of Medical Internet Research mHealth and uHealth, indicate that the app was successful in providing accessible and personalized obstetrical care, designed specifically to target preterm birth risk by focusing on high-risk pregnant women.

Preterm birth, the leading cause of neonatal death or long-term disability, is on the rise in the United States with approximately one of every 10 births occurring prior to 37 weeks of gestation, according to the researchers, and these rates are disproportionately high among some socioeconomic groups, including African Americans and families living in poverty. These patient groups often are the hardest to reach due to limited access to and attendance at routine prenatal care, the researchers contend.

“Mobile phone apps are a great way to engage a vulnerable population in their health care because approximately 86 percent of American adults own a mobile phone, regardless of racial and ethnic groups,” Tamar Krishnamurti, Ph.D., lead author and assistant research professor of engineering and public policy at CMU, said in a statement. “Moreover, 20 percent of all smartphone owners downloaded a pregnancy app in 2015. Although hundreds of pregnancy-related apps exist, few have been developed through a scientific process that is patient-centered and grounded in behavioral decision research.”

To develop the app, CMU decision scientists and Magee maternal-fetal medicine specialists conducted interviews and user testing with medical experts and women recruited from high-risk groups. Sixteen study participants from Magee’s outpatient clinic, which specializes in high-risk pregnancies, were then provided a smartphone with the preloaded app and a digital weight scale. Through the app, participants were queried daily over three months to assess such risk factors as rate of weight gain, smoking, alcohol consumption, depression and intimate partner violence. Because transportation to appointments is often a barrier to prenatal care, free transportation using Uber was incorporated into the app’s functionality.

The researchers found that use of the app was higher among participants at higher risk, as reflected in such factors as poorer daily moods or being earlier in their pregnancies. Participants had an attendance rate of 84 percent at prenatal appointments compared with the clinic norm of 50 percent. The researchers also conservatively estimated cost savings of $450 per patient over three months.

Participants voluntarily logged into the app to complete daily risk assessments, and computer algorithms delivered patient-specific risk feedback and recommendations tailored to individual users. When the app detected high-risk events such as intimate partner violence or thoughts of suicide, it sent real-time alerts to medical staff. Women were then contacted directly and linked to appropriate medical and social service resources.

“While we do not understand why certain socioeconomic groups are at a higher-risk for preterm birth, we do know that prenatal care that starts early in pregnancy is critical for a healthy baby and mother,” Hyagriv Simhan, M.D., professor, obstetrics, gynecology, and reproductive sciences, University of Pittsburgh School of Medicine, and chief, division of maternal-fetal medicine at Magee, said in a statement. “This pilot shows that smartphone apps are a promising and potentially cost-saving way to provide personalized care for the highest-risk patients.”

The researchers’ next steps include conducting a randomized controlled trial over the entire pregnancy of participants and evaluating the effects of the app on behavioral and clinical outcomes, including adverse birth outcomes.


Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More



Study: Use of EHRs Does Not Reduce Administrative Costs

A recent study by Duke University and Harvard Business School researchers found that costs for processing a single bill ranged from $20 for a primary care visit to $215 for an inpatient surgical procedure, or up to 25 percent of revenue.

Kibbe to Step Down as CEO of DirectTrust

David Kibbe, M.D., M.B.A., announced he would step down as president and CEO of DirectTrust at the end of the year.

Sequoia Project Exec Appointed to HITAC’s Interoperability Task Force

The Sequoia Project’s CIO/CTO, Eric Heflin, has been appointed to the Health Information Technology Advisory Committee’s (HITAC) U.S. Core Data for Interoperability Task Force (USCDI).

Healthcare Orgs Report Improvements in Quality, Cost Using Data and Analytics

In 2017, nearly three dozen organizations ranging in size from small community hospitals to some of the nation’s largest integrated delivery systems documented 125 improvements in quality, cost and efficiency using technology and improvement processes.

Consortium to Promote Implementation of a FHIR Genomics Platform

At this week’s HL7 Genomics Conference in Washington, D.C., a new group was introduced to promote implementation of a FHIR Genomics platform.

Cedars-Sinai Collaborates on Organs-on-Chip Precision Medicine Project

Scientists at Los Angeles-based Cedars-Sinai, in partnership with biotechnology startup Emulate, are pioneering a Patient-on-a-Chip program to help predict which disease treatments would be most effective based on a patient's genetic makeup and disease variant.